Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Currently, no data exists regarding the safety and tolerability of a combination regimen
utilizing weekly topotecan in combination with pemetrexed. Although both drugs are associated
with myelosuppression, it is hoped that the utilization of the weekly topotecan dosing
schedule will allow the drugs to be easily combined. This phase I trial will evaluate the
safety and tolerability of weekly topotecan in combination with pemetrexed in patients with
advanced solid tumors.